MedTrace Logo

Campath Maintenance in Chronic Lymphocytic Leukemia

NCT00587847 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2015-10-15

Study results available
· View outcomes & findings →

Summary

This is a study designed to test whether giving campath (also known as alemtuzumab) on a maintenance schedule will prolong the time until the patient requires chemotherapy.

Conditions

Interventions

DRUG

Campath

Campath 30 mg administered subcutaneously at varying intervals for up to 1 year

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Northwell Health

    lead OTHER

Principal Investigators

  • Kanti R. Rai, MD · Long Island Jewish Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2009-11-30
Completion
2009-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00587847 on ClinicalTrials.gov